WHAT IS CLAIMED IS:

1. A glycopeptide compound having at least one substituent of the formula:



$$-R^a-Y-R^b-(Z)_x$$

wherein

each R^a is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene;

each R^b is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided R^b is not a covalent bond when Z is hydrogen;

each Y is independently selected from the group consisting of oxygen, sulfur, $-S-S-$, $-NR^c-$, $-S(O)-$, $-SO_2-$, $-NR^cC(O)-$, $-OC(O)-$, $-NR^cSO_2-$, $-OSO_2-$, $-C(O)NR^c-$, $-C(O)O-$, $-SO_2NR^c-$, $-SO_2O-$, $-P(O)(OR^c)O-$, $-P(O)(OR^c)NR^c-$, $-OP(O)(OR^c)O-$, $-OP(O)(OR^c)NR^c-$, $-OC(O)O-$, $-NR^cC(O)O-$, $-NR^cC(O)NR^c-$, $-OC(O)NR^c-$ and $-NR^cSO_2NR^c-$;

each *Z* is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic;

each R^c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-C(O)R^d$;

each R^d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,

cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

x is 1 or 2;

and pharmaceutically acceptable salts thereof;

provided that:

(i) when Y is $-NR^c-$, R^c is alkyl of 1 to 4 carbon atoms, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;

(ii) when Y is $-C(O)NR^c-$, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;

(iii) when Y is sulfur, Z is hydrogen and R^b is alkylene, then R^b contains at least 7 carbon atoms; and

(iv) when Y is oxygen, Z is hydrogen and R^b is alkylene, then R^b contains at least 11 carbon atoms.

2. The compound of Claim 1, wherein the glycopeptide compound is substituted with from 1 to 3 substituents of the formula $-R^a-Y-R^b-(Z)_x$.

3. The compound of Claim 2, wherein each R^a is independently selected from alkylene having from 1 to 10 carbon atoms.

4. The compound of Claim 3, wherein R^a is ethylene or propylene.

5. The compound of Claim 2, wherein Z is hydrogen and R^b is alkylene of from 8 to 12 carbon atoms.

6. The compound of Claim 5, wherein R^b and Z form an *n*-octyl, *n*-nonyl, *n*-decyl, *n*-undecyl or *n*-dodecyl group.

7. The compound of Claim 2, wherein Z is aryl, cycloalkyl, cycloalkenyl, heteroaryl or heterocyclic and R^b is a covalent bond or alkylene of from 1 to 10 carbon atoms.

8. The compound of Claim 7, wherein Z is aryl and R^b is a covalent bond, methylene, $-(CH_2)_6-$, $-(CH_2)_7-$, $-(CH_2)_8-$, $-(CH_2)_9-$ or $-(CH_2)_{10}-$.

9. The compound of Claim 2, wherein each Y is independently selected from the group consisting of oxygen, sulfur, -S-S-, $-NR^c-$, $-S(O)-$, $-SO_2-$, $-NR^cC(O)-$, $-OC(O)-$, $-NR^cSO_2-$, $-C(O)NR^c-$, $-C(O)O-$ and $-SO_2NR^c-$.

10. The compound of Claim 9, wherein Y is oxygen, sulfur, $-NR^c-$ or $-NR^cSO_2-$.

11. The compound of Claim 2, wherein each *Z* is independently selected from hydrogen, aryl, cycloalkyl, heteroaryl and heterocyclic.

12. The compound of Claim 11, wherein *Z* is hydrogen or aryl.

13. The compound of Claim 12, wherein *Z* is phenyl, substituted phenyl, biphenyl, substituted biphenyl or terphenyl.

14. The compound of Claim 2, wherein the $-R^a-Y-R^b-(Z)_x$ group is selected from the group consisting of:

$-CH_2CH_2-NH-(CH_2)_9CH_3$;

$-CH_2CH_2CH_2-NH-(CH_2)_8CH_3$;

$-CH_2CH_2CH_2CH_2-NH-(CH_2)_7CH_3$;

$-CH_2CH_2-NHSO_2-(CH_2)_9CH_3$;

$-CH_2CH_2-NHSO_2-(CH_2)_{11}CH_3$;

$-CH_2CH_2-S-(CH_2)_8CH_3$;

$-CH_2CH_2-S-(CH_2)_9CH_3$;

$-CH_2CH_2-S-(CH_2)_{10}CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_8CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_9CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_3-CH=CH-(CH_2)_4CH_3$ (*trans*);

$-CH_2CH_2CH_2CH_2-S-(CH_2)_7CH_3$;

$-CH_2CH_2-S(O)-(CH_2)_9CH_3$;

$-CH_2CH_2-S-(CH_2)_6Ph$;

$-CH_2CH_2-S-(CH_2)_8Ph$;

$-CH_2CH_2CH_2-S-(CH_2)_8Ph$;

$-CH_2CH_2-NH-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2-NH-CH_2$-4-[4-$(CH_3)_2CHCH_2$-]-Ph;

$-CH_2CH_2-NH-CH_2$-4-(4-CF_3-Ph)-Ph;

$-CH_2CH_2-S-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2-S(O)-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S(O)-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S-CH_2$-4-[3,4-di-Cl-PhCH_2O-)-Ph;

$-CH_2CH_2-NHSO_2-CH_2$-4-[4-(4-Ph)-Ph]-Ph;

$-CH_2CH_2CH_2-NHSO_2-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-NHSO_2-CH_2$-4-(Ph-C≡C-)-Ph;

$-CH_2CH_2CH_2-NHSO_2$-4-(4-Cl-Ph)-Ph; and

$-CH_2CH_2CH_2-NHSO_2$-4-(naphth-2-yl)-Ph.

15. A compound of formula I:



I

wherein

R^1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-R^a-Y-R^b-(Z)_x$, or a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$;

R^2 is hydrogen or a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$;

R^3 is $-OR^c$, $-NR^cR^c$, $-O-R^a-Y-R^b-(Z)_x$, $-NR^c-R^a-Y-R^b-(Z)_x$, $-NR^cR^e$, or $-O-R^e$;

R^4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, $-R^a-Y-R^b-(Z)_x$, $-C(O)R^d$ and a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$;

R^5 is selected from the group consisting of hydrogen, halo, $-CH(R^c)-NR^cR^c$, $-CH(R^c)-NR^cR^e$ and $-CH(R^c)-NR^c-R^a-Y-R^b-(Z)_x$;

R^6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, $-R^a-Y-R^b-(Z)_x$, $-C(O)R^d$ and a saccharide group optionally substituted with $-NR^c-R^a-Y-R^b-(Z)_x$, or R^5 and R^6 can be joined, together with the atoms to which they are attached, form a heterocyclic ring optionally substituted with $-NR^c-R^a-Y-R^b-(Z)_x$;

R^7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,$-R^a-Y-R^b-(Z)_x$, and $-C(O)R^d$;

R^8 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R^9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R^{10} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic; or R^8 and R^{10} are joined to form $-Ar^1-O-Ar^2-$, where Ar^1 and Ar^2 are independently arylene or heteroarylene;

R^{11} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic, or R^{10} and R^{11} are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;

R^{12} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, $-C(O)R^d$, $-C(NH)R^d$, $-C(O)NR^cR^c$, $-C(O)OR^d$, $-C(NH)NR^cR^c$ and $-R^a-Y-R^b-(Z)_x$, or R^{11} and R^{12} are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring;

R^{13} is selected from the group consisting of hydrogen or $-OR^{14}$;

R^{14} is selected from hydrogen, $-C(O)R^d$ and a saccharide group;

each R^a is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene;

each R^b is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided R^b is not a covalent bond when Z is hydrogen;

each R^c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-C(O)R^d$;

each R^d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R^e is a saccharide group;

X^1, X^2 and X^3 are independently selected from hydrogen or chloro;

each Y is independently selected from the group consisting of oxygen, sulfur, $-S-S-$, $-NR^c-$, $-S(O)-$, $-SO_2-$, $-NR^cC(O)-$, $-OSO_2-$, $-OC(O)-$, $-NR^cSO_2-$, $-C(O)NR^c-$, $-C(O)O-$, $-SO_2NR^c-$, $-SO_2O-$, $-P(O)(OR^c)O-$,

$-P(O)(OR^c)NR^c-$, $-OP(O)(OR^c)O-$, $-OP(O)(OR^c)NR^c-$, $-OC(O)O-$, $-NR^cC(O)O-$, $-NR^cC(O)NR^c-$, $-OC(O)NR^c-$ and $-NR^cSO_2NR^c-$;

each *Z* is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic;

n is 0, 1 or 2;

x is 1 or 2;

and pharmaceutically acceptable salts, stereoisomers and prodrugs thereof;

provided that at least one of R^1, R^2, R^3, R^4, R^5, R^6, R^7 or R^{12} has a substitutent of the formula $-R^a-Y-R^b-(Z)_x$;

and further provided that:

(i) when Y is $-NR^c-$, R^c is alkyl of 1 to 4 carbon atoms, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;

(ii) when Y is $-C(O)NR^c-$, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;

(iii) when Y is sulfur, Z is hydrogen and R^b is alkylene, then R^b contains at least 7 carbon atoms; and

(iv) when Y is oxygen, Z is hydrogen and R^b is alkylene, then R^b contains at least 11 carbon atoms.

16. The compound of Claim 15, wherein R^1 is a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$.

17. The compound of Claim 16, wherein R^1 is a saccharide group of the formula:



wherein

R^{15} is $-R^a-Y-R^b-(Z)_x$; and

R^{16} is hydrogen or methyl.

18. The compound of Claim 17, wherein R^{15} is a $-R^a-Y-R^b-(Z)_x$ group selected from the group consisting of:

$-CH_2CH_2-NH-(CH_2)_9CH_3$;

$-CH_2CH_2CH_2-NH-(CH_2)_8CH_3$;

$-CH_2CH_2CH_2CH_2-NH-(CH_2)_7CH_3$;

$-CH_2CH_2-NHSO_2-(CH_2)_9CH_3$;

$-CH_2CH_2-NHSO_2-(CH_2)_{11}CH_3$;

$-CH_2CH_2-S-(CH_2)_8CH_3$;

$-CH_2CH_2-S-(CH_2)_9CH_3$;

$-CH_2CH_2-S-(CH_2)_{10}CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_8CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_9CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_3-CH=CH-(CH_2)_4CH_3$ (*trans*);

$-CH_2CH_2CH_2CH_2-S-(CH_2)_7CH_3$;

$-CH_2CH_2-S(O)-(CH_2)_9CH_3$;

$-CH_2CH_2-S-(CH_2)_6Ph$;

$-CH_2CH_2-S-(CH_2)_8Ph$;

$-CH_2CH_2CH_2-S-(CH_2)_8Ph$;

$-CH_2CH_2-NH-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2-NH-CH_2$-4-[4-$(CH_3)_2CHCH_2$-]-Ph;

$-CH_2CH_2-NH-CH_2$-4-(4-CF_3-Ph)-Ph;

$-CH_2CH_2-S-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2-S(O)-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S(O)-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S-CH_2$-4-[3,4-di-Cl-PhCH_2O-)-Ph;

$-CH_2CH_2-NHSO_2-CH_2$-4-[4-(4-Ph)-Ph]-Ph;

$-CH_2CH_2CH_2-NHSO_2-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-NHSO_2-CH_2$-4-(Ph-C≡C-)-Ph;

$-CH_2CH_2CH_2-NHSO_2$-4-(4-Cl-Ph)-Ph; and

$-CH_2CH_2CH_2-NHSO_2$-4-(naphth-2-yl)-Ph.

19. The compound of Claim 15, wherein R^3 is -OH or $-NR^cR^c$.

20. The compound of Claim 15, wherein R^5 is hydrogen, $-CH_2$-*N*-(*N*-CH_3-D-glucamine); $-CH_2-NH-CH_2CH_2-NH-(CH_2)_9CH_3$; $-CH_2-NH-CH_2CH_2-NH-(CH_2)_{11}CH_3$; $-CH_2-NH-(CH_2)_5-COOH$; and $-CH_2$-*N*-(2-amino-2-deoxygluconic acid).

21. The compound of Claim 15, wherein R^8 is $-CH_2C(O)NH_2$, $-CH_2COOH$, benzyl, 4-hydroxyphenyl or 3-chloro-4-hydroxyphenyl.

22. The compound of Claim 15, wherein R^9 is hydrogen and R^{11} is hydrogen or methyl.

23. The compound of Claim 22, wherein R^{10} is alkyl or substituted alkyl.

24. The compound of Claim 23, wherein R^{12} is hydrogen, alkyl, substituted alkyl or $-C(O)R^d$.

25. The compound of Claim 24, wherein n is 1.

26. A compound of formula II:



II

wherein

R^{21} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-R^a-Y-R^b-(Z)_x$; or a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$;

R^{22} is $-OR^c$, $-NR^cR^c$, $-O-R^a-Y-R^b-(Z)_x$ or $-NR^c-R^a-Y-R^b-(Z)_x$;

R^{23} is selected from the group consisting of hydrogen, halo, $-CH(R^c)-NR^cR^c$, $-CH(R^c)-R^e$ and $-CH(R^c)-NR^c-R^a-Y-R^b-(Z)_x$;

R^{24} is selected from the group consisting of hydrogen and lower alkyl;

R^{25} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R^{26} is selected from the group consisting of hydrogen and lower alkyl; or R^{25} and R^{26} are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;

R^{27} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, $-C(O)R^d$, $-C(NH)R^d$, $-C(O)NR^cR^c$, $-C(O)OR^d$, $-C(NH)NR^cR^c$ and $-R^a-Y-R^b-(Z)_x$, or R^{26} and R^{27} are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring;

each R^a is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene;

each R^b is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided R^b is not a covalent bond when Z is hydrogen;

each R^c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-C(O)R^d$;

each R^d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R^e is an aminosaccharide group;

each Y is independently selected from the group consisting of oxygen, sulfur, $-S-S-$, $-NR^c-$, $-S(O)-$, $-SO_2-$, $-NR^cC(O)-$, $-OSO_2-$, $-OC(O)-$, $-NR^cSO_2-$, $-C(O)NR^c-$, $-C(O)O-$, $-SO_2NR^c-$, $-SO_2O-$, $-P(O)(OR^c)O-$, $-P(O)(OR^c)NR^c-$, $-OP(O)(OR^c)O-$, $-OP(O)(OR^c)NR^c-$, $-OC(O)O-$, $-NR^cC(O)O-$, $-NR^cC(O)NR^c-$, $-OC(O)NR^c-$ and $-NR^cSO_2NR^c-$;

each *Z* is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic;

n is 0, 1 or 2;

x is 1 or 2;

and pharmaceutically acceptable salts, stereoisomers and prodrugs thereof;

provided that at least one of R^{21}, R^{22}, R^{23} or R^{27} has a substitutent of the formula $-R^a-Y-R^b-(Z)_x$;

and further provided that:

(i) when Y is $-NR^c-$, R^c is alkyl of 1 to 4 carbon atoms, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;

(ii) when Y is $-C(O)NR^c-$, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;

(iii) when Y is sulfur, Z is hydrogen and R^b is alkylene, then R^b contains at least 7 carbon atoms; and

(iv) when Y is oxygen, Z is hydrogen and R^b is alkylene, then R^b contains at least 11 carbon atoms.

27. The compound of Claim 26, wherein R^{21} is a saccharide group of the formula:



wherein

R^{15} is $-R^a-Y-R^b-(Z)_x$, and

R^{16} is hydrogen or methyl.

28. The compound of Claim 27, wherein R^{15} is a $-R^a-Y-R^b-(Z)_x$ group selected from the group consisting of:

$-CH_2CH_2-NH-(CH_2)_9CH_3$;

$-CH_2CH_2CH_2-NH-(CH_2)_8CH_3$;

$-CH_2CH_2CH_2CH_2-NH-(CH_2)_7CH_3$;

$-CH_2CH_2-NHSO_2-(CH_2)_9CH_3$;

$-CH_2CH_2-NHSO_2-(CH_2)_{11}CH_3$;

$-CH_2CH_2-S-(CH_2)_8CH_3$;

$-CH_2CH_2-S-(CH_2)_9CH_3$;

$-CH_2CH_2-S-(CH_2)_{10}CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_8CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_9CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_3-CH=CH-(CH_2)_4CH_3$ (*trans*);

$-CH_2CH_2CH_2CH_2-S-(CH_2)_7CH_3$;

$-CH_2CH_2-S(O)-(CH_2)_9CH_3$;

$-CH_2CH_2-S-(CH_2)_6Ph$;

$-CH_2CH_2-S-(CH_2)_8Ph$;

$-CH_2CH_2CH_2-S-(CH_2)_8Ph$;

$-CH_2CH_2-NH-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2-NH-CH_2$-4-[4-$(CH_3)_2CHCH_2$-]-Ph;

$-CH_2CH_2-NH-CH_2$-4-(4-CF_3-Ph)-Ph;

$-CH_2CH_2-S-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2-S(O)-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S(O)-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S-CH_2$-4-[3,4-di-Cl-PhCH_2O-)-Ph;

$-CH_2CH_2-NHSO_2-CH_2$-4-[4-(4-Ph)-Ph]-Ph;

$-CH_2CH_2CH_2-NHSO_2-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-NHSO_2-CH_2$-4-(Ph-C≡C-)-Ph;

$-CH_2CH_2CH_2-NHSO_2$-4-(4-Cl-Ph)-Ph; and

$-CH_2CH_2CH_2-NHSO_2$-4-(naphth-2-yl)-Ph.

29. The compound of Claim 26, wherein R^{22} is -OH or $-NR^cR^c$.

30. The compound of Claim 26, wherein R^{23} is hydrogen, $-CH_2$-*N*-(*N*-CH_3-D-glucamine); $-CH_2-NH-CH_2CH_2-NH-(CH_2)_9CH_3$; $-CH_2-NH-CH_2CH_2-NH-(CH_2)_{11}CH_3$; $-CH_2-NH-(CH_2)_5-COOH$; or $-CH_2$-*N*-(2-amino-2-deoxygluconic acid).

31. The compound of Claim 26, wherein R^{24} is hydrogen and R^{26} is hydrogen or methyl.

32. The compound of Claim 31, wherein R^{25} is alkyl or substituted alkyl.

33. The compound of Claim 32, wherein R^{25} is isobutyl.

34. The compound of Claim 33, wherein R^{27} is hydrogen, alkyl, substituted alkyl or $-C(O)R^d$.

35. A compound shown in any of Tables I, II, III, IV, V or VI, or a pharmaceutically-acceptable salt thereof.

36. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a glycopeptide compound having at least one substituent of the formula:

$$-R^a-Y-R^b-(Z)_x$$

wherein

each R^a is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene;

each R^b is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided R^b is not a covalent bond when Z is hydrogen;

each Y is independently selected from the group consisting of oxygen, sulfur, $-S-S-$, $-NR^c-$, $-S(O)-$, $-SO_2-$, $-NR^cC(O)-$, $-OC(O)-$, $-NR^cSO_2-$, $-OSO_2-$, $-C(O)NR^c-$, $-C(O)O-$, $-SO_2NR^c-$, $-SO_2O-$, $,-P(O)(OR^c)O-$, $-P(O)(OR^c)NR^c-$, $-OP(O)(OR^c)O-$, $-OP(O)(OR^c)NR^c-$, $-OC(O)O-$, $-NR^cC(O)O-$, $-NR^cC(O)NR^c-$, $-OC(O)NR^c-$ and $-NR^cSO_2NR^c-$;

each *Z* is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic;

each R^c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,

cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-C(O)R^d$;

each R^d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

x is 1 or 2;

and pharmaceutically acceptable salts thereof;

provided that:

(i) when Y is $-NR^c-$, R^c is alkyl of 1 to 4 carbon atoms, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;

(ii) when Y is $-C(O)NR^c-$, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;

(iii) when Y is sulfur, Z is hydrogen and R^b is alkylene, then R^b contains at least 7 carbon atoms; and

(iv) when Y is oxygen, Z is hydrogen and R^b is alkylene, then R^b contains at least 11 carbon atoms.

37. The pharmaceutical composition of Claim 36, wherein the glycopeptide compound is substituted with from 1 to 3 substituents of the formula $-R^a-Y-R^b-(Z)_x$.

38. The pharmaceutical composition of Claim 37, wherein each R^a is independently selected from alkylene having from 1 to 10 carbon atoms.

39. The pharmaceutical composition of Claim 38, wherein R^a is ethylene or propylene.

40. The pharmaceutical composition of Claim 37, wherein Z is hydrogen and R^b is alkylene of from 8 to 12 carbon atoms.

41. The pharmaceutical composition of Claim 40, wherein R^b and Z form an *n*-octyl, *n*-nonyl, *n*-decyl, *n*-undecyl or *n*-dodecyl group.

42. The pharmaceutical composition of Claim 37, wherein Z is aryl, cycloalkyl, cycloalkenyl, heteroaryl or heterocyclic and R^b is a covalent bond or alkylene of from 1 to 10 carbon atoms.

43. The pharmaceutical composition of Claim 42, wherein Z is aryl and R^b is a covalent bond, methylene, $-(CH_2)_6-$, $-(CH_2)_7-$, $-(CH_2)_8-$, $-(CH_2)_9-$ or $-(CH_2)_{10}-$.

44. The pharmaceutical composition of Claim 37, wherein each Y is independently selected from the group consisting of oxygen, sulfur, -S-S-, $-NR^c-$, $-S(O)-$, $-SO_2-$, $-NR^cC(O)-$, $-OC(O)-$, $-NR^cSO_2-$, $-C(O)NR^c-$, $-C(O)O-$ and $-SO_2NR^c-$.

45. The pharmaceutical composition of Claim 44, wherein Y is oxygen, sulfur, $-NR^c-$ or $-NR^cSO_2-$.

46. The pharmaceutical composition of Claim 37, wherein each *Z* is independently selected from hydrogen, aryl, cycloalkyl, heteroaryl and heterocyclic.

47. The pharmaceutical composition of Claim 46, wherein *Z* is hydrogen or aryl.

48. The pharmaceutical composition of Claim 47, wherein Z is phenyl, substituted phenyl, biphenyl, substituted biphenyl or terphenyl.

49. The pharmaceutical composition of Claim 37, wherein the $-R^a-Y-R^b-(Z)_x$ group is selected from the group consisting of:

$-CH_2CH_2-NH-(CH_2)_9CH_3$;

$-CH_2CH_2CH_2-NH-(CH_2)_8CH_3$;

$-CH_2CH_2CH_2CH_2-NH-(CH_2)_7CH_3$;

$-CH_2CH_2-NHSO_2-(CH_2)_9CH_3$;

$-CH_2CH_2-NHSO_2-(CH_2)_{11}CH_3$;

$-CH_2CH_2-S-(CH_2)_8CH_3$;

$-CH_2CH_2-S-(CH_2)_9CH_3$;

$-CH_2CH_2-S-(CH_2)_{10}CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_8CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_9CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_3-CH=CH-(CH_2)_4CH_3$ (*trans*);

$-CH_2CH_2CH_2CH_2-S-(CH_2)_7CH_3$;

$-CH_2CH_2-S(O)-(CH_2)_9CH_3$;

$-CH_2CH_2-S-(CH_2)_6Ph$;

$-CH_2CH_2-S-(CH_2)_8Ph$;

$-CH_2CH_2CH_2-S-(CH_2)_8Ph$;

$-CH_2CH_2-NH-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2-NH-CH_2$-4-[4-$(CH_3)_2CHCH_2$-]-Ph;

$-CH_2CH_2-NH-CH_2$-4-(4-CF_3-Ph)-Ph;

$-CH_2CH_2-S-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2-S(O)-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S(O)-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S-CH_2$-4-[3,4-di-Cl-PhCH_2O-)-Ph;

$-CH_2CH_2-NHSO_2-CH_2$-4-[4-(4-Ph)-Ph]-Ph;

$-CH_2CH_2CH_2-NHSO_2-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-NHSO_2-CH_2$-4-(Ph-C≡C-)-Ph;

$-CH_2CH_2CH_2-NHSO_2$-4-(4-Cl-Ph)-Ph; and

$-CH_2CH_2CH_2-NHSO_2$-4-(naphth-2-yl)-Ph.

50. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a compound of formula I:



I

wherein

R^1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-R^a-Y-R^b-(Z)_x$; or a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$;

R^2 is hydrogen or a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$;

R^3 is $-OR^c$, $-NR^cR^c$, $-O-R^a-Y-R^b-(Z)_x$, $-NR^c-R^a-Y-R^b-(Z)_x$, $-NR^cR^e$, or $-O-R^e$;

R^4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, $-R^a-Y-R^b-(Z)_x$, $-C(O)R^d$ and a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$;

R^5 is selected from the group consisting of hydrogen, halo, $-CH(R^c)-NR^cR^c$, $-CH(R^c)-NR^cR^e$ and $-CH(R^c)-NR^c-R^a-Y-R^b-(Z)_x$;

R^6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, $-R^a-Y-R^b-(Z)_x$, $-C(O)R^d$ and a saccharide group optionally substituted with $-NR^c-R^a-Y-R^b-(Z)_x$, or R^5 and R^6 can be joined, together with the atoms to which they are attached, form a heterocyclic ring optionally substituted with $-NR^c-R^a-Y-R^b-(Z)_x$;

R^7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, $-R^a-Y-R^b-(Z)_x$, and $-C(O)R^d$;

R^8 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R^9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R^{10} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and

heterocyclic; or R^8 and R^{10} are joined to form $-Ar^1-O-Ar^2-$, where Ar^1 and Ar^2 are independently arylene or heteroarylene;

R^{11} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic, or R^{10} and R^{11} are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;

R^{12} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, $-C(O)R^d$, $-C(NH)R^d$, $-C(O)NR^cR^c$, $-C(O)OR^d$, $-C(NH)NR^cR^c$ and $-R^a-Y-R^b-(Z)_x$, or R^{11} and R^{12} are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring;

R^{13} is selected from the group consisting of hydrogen or $-OR^{14}$;

R^{14} is selected from hydrogen, $-C(O)R^d$ and a saccharide group;

each R^a is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene;

each R^b is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided R^b is not a covalent bond when Z is hydrogen;

each R^c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-C(O)R^d$;

each R^d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,

cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R^e is a saccharide group;

X^1, X^2 and X^3 are independently selected from hydrogen or chloro;

each Y is independently selected from the group consisting of oxygen, sulfur, $-S-S-$, $-NR^c-$, $-S(O)-$, $-SO_2-$, $-NR^cC(O)-$, $-OSO_2-$, $-OC(O)-$, $-NR^cSO_2-$, $-C(O)NR^c-$, $-C(O)O-$, $-SO_2NR^c-$, $-SO_2O-$, $-P(O)(OR^c)O-$, $-P(O)(OR^c)NR^c-$, $-OP(O)(OR^c)O-$, $-OP(O)(OR^c)NR^c-$, $-OC(O)O-$, $-NR^cC(O)O-$, $-NR^cC(O)NR^c-$, $-OC(O)NR^c-$ and $-NR^cSO_2NR^c-$;

each *Z* is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic;

n is 0, 1 or 2;

x is 1 or 2;

and pharmaceutically acceptable salts, stereoisomers and prodrugs thereof;

provided that at least one of R^1, R^2, R^3, R^4, R^5, R^6, R^7 or R^{12} has a substitutent of the formula $-R^a-Y-R^b-(Z)_x$;

and further provided that:

(i) when Y is $-NR^c-$, R^c is alkyl of 1 to 4 carbon atoms, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;

(ii) when Y is $-C(O)NR^c-$, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;

(iii) when Y is sulfur, Z is hydrogen and R^b is alkylene, then R^b contains at least 7 carbon atoms; and

(iv) when Y is oxygen, Z is hydrogen and R^b is alkylene, then R^b contains at least 11 carbon atoms.

51. The pharmaceutical composition of Claim 50, wherein R^1 is a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$.

52. The pharmaceutical composition of Claim 51, wherein R^1 is a saccharide group of the formula:



wherein

R^{15} is $-R^a-Y-R^b-(Z)_x$; and

R^{16} is hydrogen or methyl.

53. The pharmaceutical composition of Claim 52, wherein R^{15} is a $-R^a-Y-R^b-(Z)_x$ group selected from the group consisting of:

$-CH_2CH_2-NH-(CH_2)_9CH_3$;

$-CH_2CH_2CH_2-NH-(CH_2)_8CH_3$;

$-CH_2CH_2CH_2CH_2-NH-(CH_2)_7CH_3$;

$-CH_2CH_2-NHSO_2-(CH_2)_9CH_3$;

$-CH_2CH_2-NHSO_2-(CH_2)_{11}CH_3$;

$-CH_2CH_2-S-(CH_2)_8CH_3$;

$-CH_2CH_2-S-(CH_2)_9CH_3$;

$-CH_2CH_2-S-(CH_2)_{10}CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_8CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_9CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_3-CH=CH-(CH_2)_4CH_3$ (*trans*);

$-CH_2CH_2CH_2CH_2-S-(CH_2)_7CH_3$;

$-CH_2CH_2-S(O)-(CH_2)_9CH_3$;

$-CH_2CH_2-S-(CH_2)_6Ph$;

$-CH_2CH_2-S-(CH_2)_8Ph$;

$-CH_2CH_2CH_2-S-(CH_2)_8Ph$;

$-CH_2CH_2-NH-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2-NH-CH_2$-4-[4-$(CH_3)_2CHCH_2$-]-Ph;

$-CH_2CH_2-NH-CH_2$-4-(4-CF_3-Ph)-Ph;

$-CH_2CH_2-S-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2-S(O)-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S(O)-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S-CH_2$-4-[3,4-di-Cl-PhCH_2O-)-Ph;

$-CH_2CH_2-NHSO_2-CH_2$-4-[4-(4-Ph)-Ph]-Ph;

$-CH_2CH_2CH_2-NHSO_2-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-NHSO_2-CH_2$-4-(Ph-C≡C-)-Ph;

$-CH_2CH_2CH_2-NHSO_2$-4-(4-Cl-Ph)-Ph; and

$-CH_2CH_2CH_2-NHSO_2$-4-(naphth-2-yl)-Ph.

54. The pharmaceutical composition of Claim 50, wherein R^3 is -OH or $-NR^cR^c$.

55. The pharmaceutical composition of Claim 50, wherein R^5 is hydrogen, $-CH_2$-*N*-(*N*-CH_3-D-glucamine); $-CH_2-NH-CH_2CH_2-NH-(CH_2)_9CH_3$; $-CH_2-NH-CH_2CH_2-NH-(CH_2)_{11}CH_3$; $-CH_2-NH-(CH_2)_5-COOH$; and $-CH_2$-*N*-(2-amino-2-deoxygluconic acid).

56. The pharmaceutical composition of Claim 50, wherein R^8 is $-CH_2C(O)NH_2$, $-CH_2COOH$, benzyl, 4-hydroxyphenyl or 3-chloro-4-hydroxyphenyl.

57. The pharmaceutical composition of Claim 50, wherein R^9 is hydrogen and R^{11} is hydrogen or methyl.

58. The pharmaceutical composition of Claim 57, wherein R^{10} is alkyl or substituted alkyl.

59. The pharmaceutical composition of Claim 58, wherein R^{12} is hydrogen, alkyl, substituted alkyl or $-C(O)R^d$.

60. The pharmaceutical composition of Claim 50, wherein *n* is 1.

61. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a compound of formula II:



II

wherein

R^{21} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-R^a-Y-R^b-(Z)_x$; or a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$;

R^{22} is $-OR^c$, $-NR^cR^c$, $-O-R^a-Y-R^b-(Z)_x$ or $-NR^c-R^a-Y-R^b-(Z)_x$;

R^{23} is selected from the group consisting of hydrogen, halo, $-CH(R^c)-NR^cR^c$, $-CH(R^c)-R^e$ and $-CH(R^c)-NR^c-R^a-Y-R^b-(Z)_x$;

R^{24} is selected from the group consisting of hydrogen and lower alkyl;

R^{25} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R^{26} is selected from the group consisting of hydrogen and lower alkyl; or R^{25} and R^{26} are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;

R^{27} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, $-C(O)R^d$, $-C(NH)R^d$, $-C(O)NR^cR^c$, $-C(O)OR^d$, $-C(NH)NR^cR^c$ and $-R^a-Y-R^b-(Z)_x$, or R^{26} and R^{27} are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring;

each R^a is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene;

each R^b is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided R^b is not a covalent bond when Z is hydrogen;

each R^c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-C(O)R^d$;

each R^d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R^e is an aminosaccharide group;

each Y is independently selected from the group consisting of oxygen, sulfur, $-S-S-$, $-NR^c-$, $-S(O)-$, $-SO_2-$, $-NR^cC(O)-$, $-OSO_2-$, $-OC(O)-$, $-NR^cSO_2-$, $-C(O)NR^c-$, $-C(O)O-$, $-SO_2NR^c-$, $-SO_2O-$, $-P(O)(OR^c)O-$, $-P(O)(OR^c)NR^c-$, $-OP(O)(OR^c)O-$, $-OP(O)(OR^c)NR^c-$, $-OC(O)O-$, $-NR^cC(O)O-$, $-NR^cC(O)NR^c-$, $-OC(O)NR^c-$ and $-NR^cSO_2NR^c-$;

each *Z* is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic;

n is 0, 1 or 2;

x is 1 or 2;

and pharmaceutically acceptable salts, stereoisomers and prodrugs thereof;

provided that at least one of R^{21}, R^{22}, R^{23} or R^{27} has a substitutent of the formula $-R^a-Y-R^b-(Z)_x$;

and further provided that:

(i) when Y is $-NR^c-$, R^c is alkyl of 1 to 4 carbon atoms, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;

(ii) when Y is $-C(O)NR^c-$, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;

(iii) when Y is sulfur, Z is hydrogen and R^b is alkylene, then R^b contains at least 7 carbon atoms; and

(iv) when Y is oxygen, Z is hydrogen and R^b is alkylene, then R^b contains at least 11 carbon atoms.

62. The pharmaceutical composition of Claim 61, wherein R^{21} is a saccharide group of the formula:



wherein

R^{15} is $-R^a-Y-R^b-(Z)_x$, and

R^{16} is hydrogen or methyl.

63. The pharmaceutical composition of Claim 62, wherein R^{15} is a $-R^a-Y-R^b-(Z)_x$ group selected from the group consisting of:

$-CH_2CH_2-NH-(CH_2)_9CH_3$;

$-CH_2CH_2CH_2-NH-(CH_2)_8CH_3$;

$-CH_2CH_2CH_2CH_2-NH-(CH_2)_7CH_3$;

$-CH_2CH_2-NHSO_2-(CH_2)_9CH_3$;

$-CH_2CH_2-NHSO_2-(CH_2)_{11}CH_3$;

$-CH_2CH_2-S-(CH_2)_8CH_3$;

$-CH_2CH_2-S-(CH_2)_9CH_3$;

$-CH_2CH_2-S-(CH_2)_{10}CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_8CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_9CH_3$;

$-CH_2CH_2CH_2-S-(CH_2)_3-CH=CH-(CH_2)_4CH_3$ (*trans*);

$-CH_2CH_2CH_2CH_2-S-(CH_2)_7CH_3$;

$-CH_2CH_2-S(O)-(CH_2)_9CH_3$;

$-CH_2CH_2-S-(CH_2)_6Ph$;

$-CH_2CH_2-S-(CH_2)_8Ph$;

$-CH_2CH_2CH_2-S-(CH_2)_8Ph$;

$-CH_2CH_2-NH-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2-NH-CH_2$-4-[4-$CH_3)_2CHCH_2$-]-Ph;

$-CH_2CH_2-NH-CH_2$-4-(4-CF_3-Ph)-Ph;

$-CH_2CH_2-S-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2-S(O)-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S(O)-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-S-CH_2$-4-[3,4-di-Cl-PhCH_2O-)-Ph;

$-CH_2CH_2-NHSO_2-CH_2$-4-[4-(4-Ph)-Ph]-Ph;

$-CH_2CH_2CH_2-NHSO_2-CH_2$-4-(4-Cl-Ph)-Ph;

$-CH_2CH_2CH_2-NHSO_2-CH_2$-4-(Ph-C≡C-)-Ph;

$-CH_2CH_2CH_2-NHSO_2-4$-(4-Cl-Ph)-Ph; and

$-CH_2CH_2CH_2-NHSO_2-4$-(naphth-2-yl)-Ph.

64. The pharmaceutical composition of Claim 61, wherein R^{22} is -OH or $-NR^cR^c$.

65. The pharmaceutical composition of Claim 61, wherein R^{23} is hydrogen, $-CH_2$-*N*-(*N*-CH_3-D-glucamine); $-CH_2-NH-CH_2CH_2-NH-(CH_2)_9CH_3$; $-CH_2-NH-CH_2CH_2-NH-(CH_2)_{11}CH_3$; $-CH_2-NH-(CH_2)_5-COOH$; or $-CH_2$-*N*-(2-amino-2-deoxygluconic acid).

66. The pharmaceutical composition of Claim 61, wherein R^{24} is hydrogen and R^{26} is hydrogen or methyl.

67. The pharmaceutical composition of Claim 66, wherein R^{25} is alkyl or substituted alkyl.

68. The pharmaceutical composition of Claim 67, wherein R^{25} is isobutyl.

69. The pharmaceutical composition of Claim 68, wherein R^{27} is hydrogen, alkyl, substituted alkyl or $-C(O)R^d$.

70. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a compound shown in any of Tables I, II, III, IV, V or VI, or a pharmaceutically-acceptable salt thereof.

71. A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition of Claim 36, 50 or 61.